Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Asthma | 133 | 2019 | 397 | 17.350 |
Why?
|
Anti-Asthmatic Agents | 32 | 2018 | 71 | 4.670 |
Why?
|
Bronchodilator Agents | 30 | 2019 | 82 | 3.870 |
Why?
|
Adrenal Cortex Hormones | 35 | 2019 | 148 | 3.120 |
Why?
|
Adrenergic beta-Agonists | 20 | 2014 | 50 | 2.470 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 15 | 2019 | 120 | 2.450 |
Why?
|
Albuterol | 19 | 2018 | 40 | 2.040 |
Why?
|
Lung | 17 | 2019 | 233 | 1.800 |
Why?
|
Eosinophils | 12 | 2019 | 48 | 1.770 |
Why?
|
Humans | 163 | 2019 | 29093 | 1.610 |
Why?
|
Scopolamine Derivatives | 4 | 2013 | 9 | 1.420 |
Why?
|
Budesonide | 7 | 2016 | 11 | 1.420 |
Why?
|
Glucocorticoids | 12 | 2019 | 149 | 1.340 |
Why?
|
Administration, Inhalation | 35 | 2019 | 92 | 1.330 |
Why?
|
Receptors, Adrenergic, beta-2 | 11 | 2019 | 36 | 1.300 |
Why?
|
Sputum | 11 | 2019 | 33 | 1.270 |
Why?
|
Adult | 88 | 2019 | 8420 | 1.250 |
Why?
|
Female | 108 | 2019 | 18164 | 1.210 |
Why?
|
Immunotherapy | 2 | 2017 | 69 | 1.170 |
Why?
|
Male | 104 | 2019 | 17807 | 1.130 |
Why?
|
Severity of Illness Index | 26 | 2019 | 863 | 1.110 |
Why?
|
Middle Aged | 69 | 2019 | 10829 | 1.000 |
Why?
|
Forced Expiratory Volume | 33 | 2019 | 112 | 0.990 |
Why?
|
Polymorphism, Single Nucleotide | 24 | 2019 | 1079 | 0.940 |
Why?
|
Phenotype | 25 | 2018 | 629 | 0.940 |
Why?
|
Adolescent | 41 | 2019 | 3254 | 0.850 |
Why?
|
Respiratory Function Tests | 21 | 2018 | 111 | 0.840 |
Why?
|
Ethanolamines | 5 | 2010 | 16 | 0.840 |
Why?
|
Polymorphism, Genetic | 6 | 2009 | 196 | 0.810 |
Why?
|
Double-Blind Method | 22 | 2019 | 501 | 0.810 |
Why?
|
Bronchial Provocation Tests | 6 | 2011 | 14 | 0.780 |
Why?
|
Leukotriene Antagonists | 6 | 2016 | 8 | 0.740 |
Why?
|
Bronchi | 8 | 2018 | 41 | 0.720 |
Why?
|
Child | 30 | 2018 | 2219 | 0.720 |
Why?
|
Genetic Predisposition to Disease | 9 | 2019 | 836 | 0.690 |
Why?
|
Antibodies, Monoclonal | 4 | 2017 | 196 | 0.670 |
Why?
|
Biological Therapy | 2 | 2017 | 20 | 0.640 |
Why?
|
Anti-Allergic Agents | 1 | 2017 | 7 | 0.630 |
Why?
|
Disease Progression | 9 | 2019 | 572 | 0.620 |
Why?
|
Immune System Diseases | 1 | 2017 | 2 | 0.610 |
Why?
|
Nasal Polyps | 1 | 2017 | 3 | 0.610 |
Why?
|
Dyspnea | 3 | 2013 | 30 | 0.600 |
Why?
|
Neutrophils | 5 | 2017 | 102 | 0.590 |
Why?
|
Genome-Wide Association Study | 12 | 2019 | 543 | 0.580 |
Why?
|
Young Adult | 25 | 2019 | 2402 | 0.550 |
Why?
|
Pharmacogenetics | 7 | 2015 | 35 | 0.550 |
Why?
|
Drug Therapy, Combination | 10 | 2019 | 273 | 0.550 |
Why?
|
Acetates | 5 | 2017 | 15 | 0.540 |
Why?
|
Quinolines | 5 | 2017 | 27 | 0.530 |
Why?
|
Nebulizers and Vaporizers | 3 | 2017 | 13 | 0.520 |
Why?
|
Inflammation | 9 | 2019 | 507 | 0.520 |
Why?
|
Cell Adhesion Molecules | 2 | 2006 | 45 | 0.500 |
Why?
|
Aged | 29 | 2019 | 9487 | 0.500 |
Why?
|
Phosphoproteins | 2 | 2006 | 54 | 0.490 |
Why?
|
Cholinergic Antagonists | 2 | 2010 | 12 | 0.470 |
Why?
|
Eosinophilia | 3 | 2018 | 16 | 0.460 |
Why?
|
Internet | 3 | 2017 | 156 | 0.440 |
Why?
|
Spirometry | 8 | 2019 | 32 | 0.440 |
Why?
|
Collagen Type III | 2 | 2003 | 13 | 0.440 |
Why?
|
Leukocyte Count | 8 | 2019 | 55 | 0.440 |
Why?
|
Respiratory Tract Infections | 3 | 2018 | 41 | 0.440 |
Why?
|
Cholecalciferol | 3 | 2018 | 21 | 0.430 |
Why?
|
Cytokines | 4 | 2017 | 243 | 0.420 |
Why?
|
Fibroblasts | 2 | 2003 | 103 | 0.420 |
Why?
|
Muscle, Smooth | 4 | 2005 | 73 | 0.410 |
Why?
|
Epithelial Cells | 2 | 2003 | 138 | 0.410 |
Why?
|
European Continental Ancestry Group | 7 | 2019 | 1131 | 0.400 |
Why?
|
Obesity | 6 | 2018 | 1063 | 0.400 |
Why?
|
Bronchoscopy | 6 | 2017 | 56 | 0.400 |
Why?
|
Sex Factors | 7 | 2018 | 631 | 0.390 |
Why?
|
Adenocarcinoma, Papillary | 1 | 2010 | 3 | 0.390 |
Why?
|
Choristoma | 1 | 2010 | 17 | 0.380 |
Why?
|
Intra-Abdominal Fat | 1 | 2010 | 61 | 0.370 |
Why?
|
Health Surveys | 2 | 2009 | 191 | 0.370 |
Why?
|
Treatment Outcome | 19 | 2017 | 3099 | 0.370 |
Why?
|
Pancreas | 1 | 2010 | 79 | 0.370 |
Why?
|
Research Design | 3 | 2018 | 286 | 0.360 |
Why?
|
Occupational Exposure | 2 | 2018 | 224 | 0.360 |
Why?
|
Immunoglobulin E | 9 | 2019 | 47 | 0.360 |
Why?
|
Ovarian Neoplasms | 1 | 2010 | 87 | 0.360 |
Why?
|
Treatment Failure | 8 | 2018 | 159 | 0.350 |
Why?
|
Alendronate | 2 | 2019 | 12 | 0.350 |
Why?
|
Receptors, Adrenergic, beta | 2 | 2006 | 13 | 0.350 |
Why?
|
Genetic Association Studies | 1 | 2009 | 148 | 0.350 |
Why?
|
Chlorofluorocarbons | 1 | 2009 | 1 | 0.350 |
Why?
|
Aerosol Propellants | 1 | 2009 | 2 | 0.340 |
Why?
|
Hydrocarbons, Fluorinated | 1 | 2009 | 4 | 0.340 |
Why?
|
Bronchial Hyperreactivity | 6 | 2015 | 22 | 0.340 |
Why?
|
Anti-Inflammatory Agents | 4 | 2015 | 90 | 0.340 |
Why?
|
United States | 15 | 2019 | 3630 | 0.340 |
Why?
|
Patient Acceptance of Health Care | 4 | 2019 | 154 | 0.330 |
Why?
|
Microfilament Proteins | 2 | 2006 | 33 | 0.330 |
Why?
|
Nitric Oxide | 8 | 2017 | 116 | 0.320 |
Why?
|
Inflammation Mediators | 2 | 2010 | 101 | 0.320 |
Why?
|
Case-Control Studies | 10 | 2019 | 859 | 0.310 |
Why?
|
Drug Resistance | 2 | 2017 | 36 | 0.300 |
Why?
|
Bronchoalveolar Lavage Fluid | 4 | 2017 | 67 | 0.300 |
Why?
|
Hypersensitivity | 1 | 2007 | 25 | 0.300 |
Why?
|
Beclomethasone | 6 | 2015 | 8 | 0.300 |
Why?
|
Peak Expiratory Flow Rate | 9 | 2018 | 15 | 0.300 |
Why?
|
Cross-Over Studies | 5 | 2019 | 94 | 0.290 |
Why?
|
Patient Education as Topic | 1 | 2009 | 251 | 0.290 |
Why?
|
Interleukin-13 | 6 | 2012 | 33 | 0.290 |
Why?
|
Clinical Trials as Topic | 6 | 2013 | 298 | 0.290 |
Why?
|
Hypersensitivity, Immediate | 2 | 2016 | 9 | 0.290 |
Why?
|
Vitamin D Deficiency | 3 | 2018 | 89 | 0.290 |
Why?
|
Risk Assessment | 7 | 2019 | 1305 | 0.290 |
Why?
|
Th2 Cells | 4 | 2016 | 14 | 0.280 |
Why?
|
Th1 Cells | 3 | 2013 | 18 | 0.280 |
Why?
|
Animals | 8 | 2017 | 7297 | 0.270 |
Why?
|
Dietary Supplements | 2 | 2018 | 170 | 0.270 |
Why?
|
Prospective Studies | 8 | 2019 | 2019 | 0.270 |
Why?
|
Genetic Loci | 3 | 2019 | 147 | 0.270 |
Why?
|
Skin | 2 | 2017 | 203 | 0.270 |
Why?
|
Arginase | 3 | 2010 | 8 | 0.260 |
Why?
|
Pregnadienediols | 2 | 2015 | 2 | 0.260 |
Why?
|
Paranasal Sinuses | 2 | 2015 | 6 | 0.260 |
Why?
|
Allergy and Immunology | 1 | 2004 | 3 | 0.260 |
Why?
|
Genotype | 10 | 2016 | 735 | 0.260 |
Why?
|
Hispanic Americans | 2 | 2016 | 904 | 0.250 |
Why?
|
Risk Factors | 9 | 2018 | 3531 | 0.250 |
Why?
|
Prognosis | 5 | 2018 | 1362 | 0.240 |
Why?
|
Postural Balance | 1 | 2016 | 160 | 0.240 |
Why?
|
Pesticides | 1 | 2016 | 189 | 0.230 |
Why?
|
Transforming Growth Factors | 1 | 2003 | 3 | 0.230 |
Why?
|
Antigenic Modulation | 1 | 2003 | 2 | 0.230 |
Why?
|
Anti-Bacterial Agents | 3 | 2018 | 285 | 0.230 |
Why?
|
Actins | 1 | 2003 | 52 | 0.230 |
Why?
|
Airway Obstruction | 4 | 2013 | 31 | 0.230 |
Why?
|
Signal Transduction | 5 | 2018 | 666 | 0.220 |
Why?
|
Emigrants and Immigrants | 1 | 2016 | 235 | 0.220 |
Why?
|
Vital Capacity | 5 | 2018 | 44 | 0.220 |
Why?
|
Transients and Migrants | 1 | 2016 | 281 | 0.220 |
Why?
|
Haplotypes | 4 | 2010 | 220 | 0.220 |
Why?
|
Biopsy | 4 | 2017 | 241 | 0.220 |
Why?
|
Practice Guidelines as Topic | 4 | 2017 | 374 | 0.220 |
Why?
|
Recurrence | 3 | 2017 | 235 | 0.210 |
Why?
|
Myofibrils | 1 | 2002 | 10 | 0.210 |
Why?
|
Cohort Studies | 9 | 2019 | 1687 | 0.210 |
Why?
|
Breath Tests | 5 | 2017 | 17 | 0.210 |
Why?
|
Receptors, Glucocorticoid | 3 | 2011 | 8 | 0.210 |
Why?
|
Age of Onset | 5 | 2012 | 95 | 0.200 |
Why?
|
African Americans | 6 | 2019 | 1373 | 0.200 |
Why?
|
Disease Management | 3 | 2017 | 114 | 0.200 |
Why?
|
Arginine | 2 | 2012 | 17 | 0.200 |
Why?
|
Comorbidity | 4 | 2017 | 540 | 0.200 |
Why?
|
Aging | 3 | 2017 | 881 | 0.190 |
Why?
|
Age Factors | 8 | 2017 | 1108 | 0.190 |
Why?
|
Amino Acids | 2 | 2019 | 41 | 0.190 |
Why?
|
Idiopathic Pulmonary Fibrosis | 1 | 2019 | 6 | 0.180 |
Why?
|
Child, Preschool | 7 | 2019 | 1167 | 0.180 |
Why?
|
Lung Diseases, Interstitial | 1 | 2019 | 9 | 0.180 |
Why?
|
Prevalence | 3 | 2007 | 896 | 0.180 |
Why?
|
Respiratory Sounds | 1 | 2019 | 10 | 0.170 |
Why?
|
Muscarinic Antagonists | 1 | 2019 | 15 | 0.170 |
Why?
|
Emergency Service, Hospital | 2 | 2019 | 430 | 0.170 |
Why?
|
T-Lymphocytes | 2 | 2011 | 114 | 0.170 |
Why?
|
T-Lymphocyte Subsets | 2 | 2010 | 22 | 0.170 |
Why?
|
Androstadienes | 4 | 2010 | 17 | 0.170 |
Why?
|
Smoking | 2 | 2019 | 427 | 0.170 |
Why?
|
Corynebacterium | 1 | 2018 | 1 | 0.170 |
Why?
|
Moraxella | 1 | 2018 | 3 | 0.170 |
Why?
|
Aspirin | 1 | 2018 | 61 | 0.170 |
Why?
|
Sleep | 1 | 2019 | 86 | 0.170 |
Why?
|
Cluster Analysis | 3 | 2013 | 128 | 0.160 |
Why?
|
Preoperative Care | 1 | 2019 | 110 | 0.160 |
Why?
|
Patient Care Team | 1 | 2019 | 124 | 0.160 |
Why?
|
Guideline Adherence | 1 | 2019 | 110 | 0.160 |
Why?
|
Multivariate Analysis | 6 | 2018 | 637 | 0.160 |
Why?
|
Hydroxyurea | 1 | 2018 | 3 | 0.160 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2018 | 57 | 0.160 |
Why?
|
Gonadal Steroid Hormones | 1 | 2018 | 28 | 0.160 |
Why?
|
Interleukin-4 | 2 | 2012 | 20 | 0.160 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2017 | 15 | 0.160 |
Why?
|
Indoleacetic Acids | 1 | 2017 | 2 | 0.160 |
Why?
|
Laboratories | 1 | 2017 | 13 | 0.160 |
Why?
|
Shewanella putrefaciens | 1 | 2017 | 1 | 0.160 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2018 | 464 | 0.160 |
Why?
|
Body Mass Index | 6 | 2018 | 865 | 0.160 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2017 | 13 | 0.160 |
Why?
|
Soft Tissue Infections | 1 | 2017 | 10 | 0.160 |
Why?
|
Pathology | 1 | 2017 | 20 | 0.150 |
Why?
|
Pyridines | 1 | 2017 | 78 | 0.150 |
Why?
|
Autoimmunity | 1 | 2017 | 26 | 0.150 |
Why?
|
Hand | 1 | 2017 | 63 | 0.150 |
Why?
|
Sleep Apnea Syndromes | 1 | 2017 | 27 | 0.150 |
Why?
|
Membrane Glycoproteins | 2 | 2011 | 97 | 0.150 |
Why?
|
Ibuprofen | 1 | 2016 | 4 | 0.150 |
Why?
|
Emphysema | 1 | 2016 | 5 | 0.150 |
Why?
|
Blood Proteins | 1 | 2016 | 18 | 0.150 |
Why?
|
Delayed-Action Preparations | 1 | 2016 | 35 | 0.150 |
Why?
|
Self Care | 1 | 2017 | 137 | 0.140 |
Why?
|
Acetaminophen | 1 | 2016 | 18 | 0.140 |
Why?
|
Patient Readmission | 1 | 2017 | 105 | 0.140 |
Why?
|
Fluocinolone Acetonide | 2 | 2009 | 7 | 0.140 |
Why?
|
Biomedical Research | 3 | 2012 | 153 | 0.140 |
Why?
|
Antibodies, Anti-Idiotypic | 2 | 2006 | 7 | 0.140 |
Why?
|
Medicare | 1 | 2017 | 186 | 0.140 |
Why?
|
Azithromycin | 1 | 2015 | 14 | 0.140 |
Why?
|
Respiratory System | 2 | 2007 | 12 | 0.140 |
Why?
|
Skin Diseases | 1 | 2017 | 138 | 0.140 |
Why?
|
Aged, 80 and over | 7 | 2018 | 3717 | 0.130 |
Why?
|
Secondary Prevention | 1 | 2015 | 59 | 0.130 |
Why?
|
African Continental Ancestry Group | 1 | 2017 | 350 | 0.130 |
Why?
|
Linkage Disequilibrium | 6 | 2012 | 192 | 0.130 |
Why?
|
Outpatients | 1 | 2015 | 49 | 0.130 |
Why?
|
Bacteria | 2 | 2016 | 45 | 0.130 |
Why?
|
Peptide Fragments | 1 | 2018 | 422 | 0.130 |
Why?
|
Predictive Value of Tests | 2 | 2014 | 787 | 0.130 |
Why?
|
Palliative Care | 1 | 2015 | 47 | 0.130 |
Why?
|
Odds Ratio | 5 | 2015 | 447 | 0.130 |
Why?
|
Reproducibility of Results | 3 | 2014 | 726 | 0.130 |
Why?
|
Interleukin-1 | 2 | 2005 | 33 | 0.130 |
Why?
|
Pregnenediones | 1 | 2014 | 2 | 0.130 |
Why?
|
Granulocytes | 2 | 2013 | 12 | 0.120 |
Why?
|
Uncertainty | 1 | 2014 | 12 | 0.120 |
Why?
|
Diagnostic Techniques, Respiratory System | 1 | 2014 | 1 | 0.120 |
Why?
|
Clarithromycin | 2 | 2010 | 2 | 0.120 |
Why?
|
Edetic Acid | 1 | 2014 | 8 | 0.120 |
Why?
|
Serum | 1 | 2014 | 20 | 0.120 |
Why?
|
Plasma | 1 | 2014 | 15 | 0.120 |
Why?
|
Zinc Fingers | 1 | 2013 | 8 | 0.120 |
Why?
|
Patient Preference | 1 | 2014 | 38 | 0.120 |
Why?
|
Brain Death | 1 | 2014 | 27 | 0.120 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2007 | 200 | 0.120 |
Why?
|
Drug Administration Schedule | 6 | 2015 | 246 | 0.120 |
Why?
|
Tissue and Organ Harvesting | 1 | 2014 | 35 | 0.120 |
Why?
|
Vitamins | 1 | 2014 | 58 | 0.120 |
Why?
|
Repressor Proteins | 1 | 2013 | 53 | 0.120 |
Why?
|
Gene Expression | 2 | 2012 | 332 | 0.120 |
Why?
|
Multifactorial Inheritance | 1 | 2013 | 19 | 0.120 |
Why?
|
Pulmonary Diffusing Capacity | 1 | 2013 | 2 | 0.120 |
Why?
|
Kv Channel-Interacting Proteins | 1 | 2013 | 3 | 0.110 |
Why?
|
Interferon-gamma | 4 | 2010 | 51 | 0.110 |
Why?
|
Liver Transplantation | 1 | 2014 | 111 | 0.110 |
Why?
|
Receptors, Tumor Necrosis Factor | 2 | 2003 | 45 | 0.110 |
Why?
|
Interleukin-4 Receptor alpha Subunit | 1 | 2012 | 6 | 0.110 |
Why?
|
Macrolides | 1 | 2012 | 8 | 0.110 |
Why?
|
Receptors, Interleukin-6 | 1 | 2012 | 13 | 0.110 |
Why?
|
Carrier Proteins | 2 | 2011 | 131 | 0.110 |
Why?
|
Dinoprostone | 3 | 2006 | 37 | 0.100 |
Why?
|
RNA, Ribosomal, 16S | 3 | 2018 | 13 | 0.100 |
Why?
|
Chronic Disease | 3 | 2014 | 369 | 0.100 |
Why?
|
Metered Dose Inhalers | 2 | 2008 | 5 | 0.100 |
Why?
|
Proteins | 1 | 2012 | 140 | 0.100 |
Why?
|
Acute Disease | 3 | 2018 | 239 | 0.100 |
Why?
|
Tobacco Smoke Pollution | 1 | 2011 | 37 | 0.100 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2018 | 641 | 0.100 |
Why?
|
Retrospective Studies | 6 | 2017 | 3111 | 0.100 |
Why?
|
Liver | 1 | 2014 | 464 | 0.100 |
Why?
|
Incidental Findings | 1 | 2010 | 26 | 0.100 |
Why?
|
Time Factors | 3 | 2011 | 2001 | 0.090 |
Why?
|
Preferred Provider Organizations | 1 | 2010 | 2 | 0.090 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2010 | 49 | 0.090 |
Why?
|
Cross-Sectional Studies | 4 | 2018 | 1356 | 0.090 |
Why?
|
Health Maintenance Organizations | 1 | 2010 | 13 | 0.090 |
Why?
|
Insurance Claim Review | 1 | 2010 | 27 | 0.090 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2010 | 10 | 0.090 |
Why?
|
HLA-DQ Antigens | 1 | 2010 | 9 | 0.090 |
Why?
|
HLA-DR Antigens | 1 | 2010 | 8 | 0.090 |
Why?
|
DNA Repair Enzymes | 1 | 2010 | 16 | 0.090 |
Why?
|
Drug Dosage Calculations | 1 | 2010 | 7 | 0.090 |
Why?
|
Lymphatic Metastasis | 1 | 2010 | 156 | 0.090 |
Why?
|
Lymph Node Excision | 1 | 2010 | 89 | 0.090 |
Why?
|
Logistic Models | 4 | 2015 | 727 | 0.090 |
Why?
|
Drug Synergism | 1 | 2010 | 67 | 0.090 |
Why?
|
Allergens | 2 | 2016 | 16 | 0.090 |
Why?
|
Superoxide Dismutase | 2 | 2011 | 47 | 0.090 |
Why?
|
Sample Size | 1 | 2009 | 37 | 0.090 |
Why?
|
Influenza Vaccines | 1 | 2010 | 78 | 0.090 |
Why?
|
Lymphocyte Activation | 2 | 2010 | 80 | 0.090 |
Why?
|
DNA-Binding Proteins | 1 | 2010 | 142 | 0.090 |
Why?
|
Influenza, Human | 1 | 2010 | 122 | 0.090 |
Why?
|
Patients | 1 | 2009 | 46 | 0.090 |
Why?
|
Heat-Shock Proteins | 1 | 2009 | 28 | 0.090 |
Why?
|
Infant | 3 | 2016 | 969 | 0.080 |
Why?
|
ROC Curve | 3 | 2017 | 149 | 0.080 |
Why?
|
Diagnosis, Differential | 1 | 2010 | 493 | 0.080 |
Why?
|
Cells, Cultured | 5 | 2010 | 799 | 0.080 |
Why?
|
Safety | 1 | 2008 | 72 | 0.080 |
Why?
|
Receptors, Leukotriene | 1 | 2008 | 4 | 0.080 |
Why?
|
Linear Models | 3 | 2018 | 426 | 0.080 |
Why?
|
Receptors, Muscarinic | 1 | 2008 | 10 | 0.080 |
Why?
|
Bronchoconstriction | 1 | 2007 | 2 | 0.080 |
Why?
|
Neutrophil Activation | 1 | 2007 | 5 | 0.080 |
Why?
|
Airway Resistance | 1 | 2007 | 5 | 0.080 |
Why?
|
North Carolina | 2 | 2017 | 1423 | 0.080 |
Why?
|
Attitude to Health | 1 | 2009 | 148 | 0.080 |
Why?
|
Amino Acid Substitution | 1 | 2007 | 40 | 0.080 |
Why?
|
Apoptosis | 3 | 2006 | 337 | 0.080 |
Why?
|
Physician-Patient Relations | 1 | 2009 | 169 | 0.080 |
Why?
|
Rhinitis | 1 | 2007 | 11 | 0.080 |
Why?
|
Sinusitis | 1 | 2007 | 17 | 0.070 |
Why?
|
Phospholipases A | 2 | 2005 | 28 | 0.070 |
Why?
|
Isoproterenol | 1 | 2006 | 18 | 0.070 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 152 | 0.070 |
Why?
|
HSP70 Heat-Shock Proteins | 1 | 2007 | 25 | 0.070 |
Why?
|
Quantitative Trait Loci | 2 | 2018 | 140 | 0.070 |
Why?
|
Ocular Hypertension | 1 | 2006 | 6 | 0.070 |
Why?
|
Pituitary-Adrenal System | 1 | 2006 | 24 | 0.070 |
Why?
|
Cataract | 1 | 2006 | 5 | 0.070 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2006 | 34 | 0.070 |
Why?
|
Risk | 2 | 2018 | 289 | 0.070 |
Why?
|
Glaucoma | 1 | 2006 | 11 | 0.070 |
Why?
|
Longitudinal Studies | 2 | 2019 | 720 | 0.070 |
Why?
|
Patient Selection | 1 | 2008 | 257 | 0.070 |
Why?
|
Bronchoalveolar Lavage | 2 | 2005 | 15 | 0.070 |
Why?
|
Cost of Illness | 1 | 2006 | 63 | 0.070 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 2005 | 9 | 0.070 |
Why?
|
CpG Islands | 1 | 2005 | 44 | 0.070 |
Why?
|
Oligodeoxyribonucleotides | 1 | 2005 | 17 | 0.070 |
Why?
|
Respiratory Mucosa | 1 | 2005 | 10 | 0.070 |
Why?
|
MAP Kinase Signaling System | 1 | 2005 | 57 | 0.070 |
Why?
|
Dermatitis, Atopic | 1 | 2007 | 86 | 0.070 |
Why?
|
Tosyl Compounds | 1 | 2005 | 4 | 0.070 |
Why?
|
Pregnancy Complications | 1 | 2006 | 80 | 0.070 |
Why?
|
Phosphorylation | 1 | 2006 | 225 | 0.070 |
Why?
|
Respiratory Physiological Phenomena | 1 | 2005 | 6 | 0.070 |
Why?
|
Trachea | 1 | 2005 | 55 | 0.070 |
Why?
|
Rhinitis, Allergic, Perennial | 1 | 2005 | 7 | 0.070 |
Why?
|
Lung Diseases | 1 | 2005 | 45 | 0.070 |
Why?
|
Regression Analysis | 2 | 2017 | 274 | 0.070 |
Why?
|
Neovascularization, Physiologic | 1 | 2005 | 106 | 0.070 |
Why?
|
Bone Density | 1 | 2006 | 182 | 0.060 |
Why?
|
Interleukin-2 | 3 | 2010 | 33 | 0.060 |
Why?
|
Follow-Up Studies | 3 | 2018 | 2108 | 0.060 |
Why?
|
Ethnic Groups | 1 | 2007 | 440 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 2 | 2019 | 871 | 0.060 |
Why?
|
Interleukin-5 | 1 | 2003 | 7 | 0.060 |
Why?
|
Pregnancy | 1 | 2006 | 815 | 0.060 |
Why?
|
Leukotriene D4 | 1 | 2003 | 2 | 0.060 |
Why?
|
Endpoint Determination | 1 | 2003 | 19 | 0.060 |
Why?
|
Patient Compliance | 2 | 2019 | 208 | 0.060 |
Why?
|
Killer Cells, Natural | 1 | 2002 | 24 | 0.050 |
Why?
|
Methacholine Chloride | 3 | 2007 | 5 | 0.050 |
Why?
|
Algorithms | 2 | 2017 | 462 | 0.050 |
Why?
|
Blotting, Western | 1 | 2002 | 281 | 0.050 |
Why?
|
Membrane Proteins | 1 | 2002 | 256 | 0.050 |
Why?
|
Cell Culture Techniques | 1 | 2002 | 165 | 0.050 |
Why?
|
TATA Box Binding Protein-Like Proteins | 1 | 2019 | 1 | 0.050 |
Why?
|
Mucin-5B | 1 | 2019 | 3 | 0.050 |
Why?
|
beta Karyopherins | 1 | 2019 | 7 | 0.050 |
Why?
|
Administration, Oral | 2 | 2014 | 169 | 0.050 |
Why?
|
Base Sequence | 2 | 2013 | 240 | 0.050 |
Why?
|
Placebos | 2 | 2012 | 61 | 0.050 |
Why?
|
Isoleucine | 1 | 2019 | 8 | 0.050 |
Why?
|
Tryptophan | 1 | 2019 | 5 | 0.040 |
Why?
|
Valine | 1 | 2019 | 17 | 0.040 |
Why?
|
Leucine | 1 | 2019 | 24 | 0.040 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2019 | 59 | 0.040 |
Why?
|
Metabolomics | 1 | 2019 | 45 | 0.040 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 2019 | 8 | 0.040 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 1 | 2019 | 14 | 0.040 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 1 | 2019 | 17 | 0.040 |
Why?
|
Fibrinogen | 1 | 2019 | 42 | 0.040 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2019 | 47 | 0.040 |
Why?
|
Promoter Regions, Genetic | 1 | 2019 | 212 | 0.040 |
Why?
|
Skin Tests | 2 | 2010 | 15 | 0.040 |
Why?
|
Flow Cytometry | 2 | 2010 | 171 | 0.040 |
Why?
|
Polymerase Chain Reaction | 2 | 2010 | 172 | 0.040 |
Why?
|
Vitamin D-Binding Protein | 1 | 2018 | 10 | 0.040 |
Why?
|
Nose | 1 | 2018 | 12 | 0.040 |
Why?
|
Incidence | 2 | 2016 | 1119 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2019 | 263 | 0.040 |
Why?
|
Puberty | 1 | 2018 | 8 | 0.040 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2018 | 82 | 0.040 |
Why?
|
Growth | 1 | 2018 | 7 | 0.040 |
Why?
|
Mouth Mucosa | 1 | 2018 | 29 | 0.040 |
Why?
|
Leukotrienes | 1 | 2018 | 4 | 0.040 |
Why?
|
Current Procedural Terminology | 1 | 2017 | 4 | 0.040 |
Why?
|
C-Reactive Protein | 1 | 2019 | 232 | 0.040 |
Why?
|
Inspiratory Capacity | 1 | 2017 | 2 | 0.040 |
Why?
|
Immunocompetence | 1 | 2017 | 12 | 0.040 |
Why?
|
Patient Care | 1 | 2017 | 33 | 0.040 |
Why?
|
Hand Injuries | 1 | 2017 | 24 | 0.040 |
Why?
|
Quality of Life | 2 | 2014 | 816 | 0.040 |
Why?
|
Foreign Bodies | 1 | 2017 | 29 | 0.040 |
Why?
|
Medication Adherence | 1 | 2019 | 144 | 0.040 |
Why?
|
Specialization | 1 | 2017 | 30 | 0.040 |
Why?
|
Workflow | 1 | 2017 | 20 | 0.040 |
Why?
|
Prednisolone | 1 | 2017 | 10 | 0.040 |
Why?
|
Reference Values | 2 | 2011 | 224 | 0.040 |
Why?
|
Disease Susceptibility | 1 | 2017 | 53 | 0.040 |
Why?
|
RNA, Bacterial | 1 | 2016 | 4 | 0.040 |
Why?
|
Bronchoconstrictor Agents | 2 | 2007 | 3 | 0.040 |
Why?
|
Cell Line | 1 | 2018 | 449 | 0.040 |
Why?
|
Sex Distribution | 1 | 2017 | 186 | 0.040 |
Why?
|
ABO Blood-Group System | 1 | 2016 | 19 | 0.040 |
Why?
|
Chi-Square Distribution | 1 | 2017 | 293 | 0.040 |
Why?
|
Fever | 1 | 2016 | 56 | 0.040 |
Why?
|
Forced Expiratory Flow Rates | 1 | 2015 | 3 | 0.040 |
Why?
|
Socioeconomic Factors | 1 | 2017 | 391 | 0.040 |
Why?
|
RNA, Messenger | 1 | 2018 | 514 | 0.030 |
Why?
|
Drug Resistance, Bacterial | 1 | 2015 | 38 | 0.030 |
Why?
|
Accidental Falls | 1 | 2017 | 204 | 0.030 |
Why?
|
Phospholipases A2 | 2 | 2005 | 22 | 0.030 |
Why?
|
Nutrition Surveys | 1 | 2016 | 134 | 0.030 |
Why?
|
Administration, Intranasal | 1 | 2014 | 30 | 0.030 |
Why?
|
Triamcinolone | 2 | 2005 | 11 | 0.030 |
Why?
|
Ionophores | 2 | 2005 | 5 | 0.030 |
Why?
|
Calcimycin | 2 | 2005 | 7 | 0.030 |
Why?
|
Tetradecanoylphorbol Acetate | 2 | 2005 | 12 | 0.030 |
Why?
|
F-Box Proteins | 1 | 2014 | 4 | 0.030 |
Why?
|
Combined Modality Therapy | 2 | 2006 | 525 | 0.030 |
Why?
|
New Jersey | 1 | 2014 | 10 | 0.030 |
Why?
|
Protease Inhibitors | 1 | 2014 | 14 | 0.030 |
Why?
|
Cell Survival | 2 | 2006 | 272 | 0.030 |
Why?
|
Pain | 1 | 2016 | 282 | 0.030 |
Why?
|
Observer Variation | 1 | 2014 | 96 | 0.030 |
Why?
|
Liver Cirrhosis | 1 | 2014 | 75 | 0.030 |
Why?
|
Interferon Regulatory Factor-2 | 1 | 2013 | 5 | 0.030 |
Why?
|
STAT4 Transcription Factor | 1 | 2013 | 16 | 0.030 |
Why?
|
Fatty Liver | 1 | 2014 | 66 | 0.030 |
Why?
|
Interleukin-12 | 1 | 2013 | 26 | 0.030 |
Why?
|
Single-Blind Method | 2 | 2004 | 165 | 0.030 |
Why?
|
Nuclear Pore | 1 | 2012 | 3 | 0.030 |
Why?
|
Prednisone | 1 | 2012 | 43 | 0.030 |
Why?
|
Biomarkers, Pharmacological | 1 | 2012 | 5 | 0.030 |
Why?
|
Tissue Donors | 1 | 2014 | 167 | 0.030 |
Why?
|
3' Untranslated Regions | 1 | 2012 | 25 | 0.030 |
Why?
|
Homozygote | 1 | 2012 | 57 | 0.030 |
Why?
|
Airway Remodeling | 1 | 2011 | 5 | 0.030 |
Why?
|
Hydrocortisone | 2 | 2002 | 61 | 0.030 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2012 | 74 | 0.030 |
Why?
|
Total Lung Capacity | 1 | 2011 | 1 | 0.030 |
Why?
|
Chromosomes, Human, Pair 4 | 1 | 2011 | 10 | 0.030 |
Why?
|
Chromosomes, Human, Pair 10 | 1 | 2011 | 8 | 0.030 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2011 | 9 | 0.030 |
Why?
|
Alleles | 1 | 2012 | 251 | 0.030 |
Why?
|
Clinical Protocols | 1 | 2011 | 95 | 0.030 |
Why?
|
Thrombospondins | 1 | 2011 | 7 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2012 | 225 | 0.030 |
Why?
|
Leptin | 1 | 2011 | 66 | 0.030 |
Why?
|
Asian Continental Ancestry Group | 1 | 2011 | 110 | 0.020 |
Why?
|
Receptors, Notch | 1 | 2011 | 16 | 0.020 |
Why?
|
Exhalation | 1 | 2010 | 4 | 0.020 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2010 | 28 | 0.020 |
Why?
|
Chlamydophila pneumoniae | 1 | 2010 | 4 | 0.020 |
Why?
|
Phylogeny | 1 | 2010 | 58 | 0.020 |
Why?
|
Mycoplasma pneumoniae | 1 | 2010 | 5 | 0.020 |
Why?
|
Hospitalization | 1 | 2014 | 417 | 0.020 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2010 | 66 | 0.020 |
Why?
|
Receptors, Cell Surface | 1 | 2011 | 72 | 0.020 |
Why?
|
Lymphocyte Count | 1 | 2010 | 23 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2011 | 90 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2010 | 49 | 0.020 |
Why?
|
Environmental Exposure | 1 | 2011 | 87 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2010 | 155 | 0.020 |
Why?
|
Protein Array Analysis | 1 | 2010 | 16 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2011 | 532 | 0.020 |
Why?
|
Discriminant Analysis | 1 | 2009 | 18 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2010 | 248 | 0.020 |
Why?
|
Vaccination | 1 | 2010 | 123 | 0.020 |
Why?
|
Pilot Projects | 1 | 2010 | 469 | 0.020 |
Why?
|
Gene Frequency | 1 | 2009 | 225 | 0.020 |
Why?
|
Biological Availability | 1 | 2008 | 21 | 0.020 |
Why?
|
Models, Statistical | 1 | 2009 | 163 | 0.020 |
Why?
|
London | 1 | 2007 | 3 | 0.020 |
Why?
|
Lung Volume Measurements | 1 | 2007 | 5 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2007 | 82 | 0.020 |
Why?
|
Motor Activity | 1 | 2010 | 310 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2009 | 222 | 0.020 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2007 | 20 | 0.020 |
Why?
|
DNA Primers | 1 | 2007 | 87 | 0.020 |
Why?
|
Cyclic AMP-Dependent Protein Kinase Type II | 1 | 2006 | 1 | 0.020 |
Why?
|
Hypertension | 1 | 2014 | 906 | 0.020 |
Why?
|
Mice | 1 | 2013 | 2368 | 0.020 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 2006 | 18 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2006 | 139 | 0.020 |
Why?
|
Microsomes | 1 | 2005 | 14 | 0.020 |
Why?
|
Cytosol | 1 | 2005 | 25 | 0.020 |
Why?
|
Cyclooxygenase 1 | 1 | 2005 | 23 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 37 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 44 | 0.020 |
Why?
|
Protein Kinases | 1 | 2005 | 28 | 0.020 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 32 | 0.020 |
Why?
|
Carcinogens | 1 | 2005 | 34 | 0.020 |
Why?
|
Oxytocics | 1 | 2005 | 11 | 0.020 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 36 | 0.020 |
Why?
|
Protein Kinase C | 1 | 2005 | 37 | 0.020 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2006 | 145 | 0.020 |
Why?
|
Cyclooxygenase 2 | 1 | 2005 | 50 | 0.020 |
Why?
|
Glutathione Peroxidase | 1 | 2005 | 8 | 0.020 |
Why?
|
NF-kappa B | 1 | 2005 | 75 | 0.020 |
Why?
|
Antigens, CD | 1 | 2005 | 100 | 0.020 |
Why?
|
Cell Count | 1 | 2005 | 50 | 0.020 |
Why?
|
Glutathione | 1 | 2005 | 37 | 0.020 |
Why?
|
Delivery of Health Care | 1 | 2007 | 142 | 0.020 |
Why?
|
Genetic Variation | 1 | 2006 | 251 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 2005 | 162 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2005 | 91 | 0.020 |
Why?
|
Periodicals as Topic | 1 | 2005 | 95 | 0.010 |
Why?
|
Oxidative Stress | 1 | 2005 | 223 | 0.010 |
Why?
|
BH3 Interacting Domain Death Agonist Protein | 1 | 2003 | 2 | 0.010 |
Why?
|
Caspase 9 | 1 | 2003 | 7 | 0.010 |
Why?
|
Caspase 8 | 1 | 2003 | 9 | 0.010 |
Why?
|
Caspases | 1 | 2003 | 31 | 0.010 |
Why?
|
Tumor Necrosis Factor Decoy Receptors | 1 | 2002 | 3 | 0.010 |
Why?
|
Immune Sera | 1 | 2002 | 9 | 0.010 |
Why?
|
Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2002 | 6 | 0.010 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 1 | 2002 | 10 | 0.010 |
Why?
|
Solubility | 1 | 2002 | 38 | 0.010 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2002 | 33 | 0.010 |
Why?
|
Survival Rate | 1 | 2005 | 795 | 0.010 |
Why?
|
Lymphocyte Subsets | 1 | 2002 | 7 | 0.010 |
Why?
|
Probability | 1 | 2002 | 150 | 0.010 |
Why?
|
Cell Division | 1 | 2002 | 97 | 0.010 |
Why?
|
Cell Movement | 1 | 2002 | 161 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2002 | 598 | 0.010 |
Why?
|